How to Build a Better Blood Stem Cell and Why It Matters

Imagine a cell so powerful that it can regenerate your entire blood system. Now imagine growing that cell in a lab dish, tailoring it for transplantation, and using it to treat patients with leukaemia, bone marrow failure, or rare immunodeficiencies, all without needing a donor match. That’s the promise driving a new wave of regenerative medicine research.

At the Australian Regenerative Medicine Institute (ARMI) at Monash University, Dr Jan Manent and colleagues in the McGlinn Lab are working on the cellular origin story of blood itself. Their focus? Hematopoietic stem cells, or HSCs, the rare cells in our bone marrow that generate all blood and immune cells for life.

Where blood begins

In mice, definitive HSCs arise during a dramatic 48-hour window in early embryonic development. “Every blood cell for the entire life of the mouse comes from that moment,” says Dr Manent. “It’s astonishing, and it’s the window we’re trying to understand.”

Using an advanced 3D imaging pipeline, the team has captured stunning views of these stem cells as they first emerge from the dorsal aorta, the embryo’s first major vessel. The results can even be explored in virtual reality, offering scientists an immersive way to study development in space and time.

But this isn’t just about beautiful pictures. It’s about engineering the future.

A genetic edge

In collaboration with leading stem cell researchers Andrew Elefanty and Elizabeth Ng at Murdoch Children’s Research Institute, Dr Manent is exploring how to guide pluripotent stem cells, cells with the capacity to become any tissue, into forming HSCs in the lab.

The approach centres on revealing gene networks that regulate stem cell “fitness”, how well a cell can engraft and compete in the bone marrow environment. “In our mouse models, we aim to tweak these gene networks such that the modified cells consistently outcompete normal ones,” explains Dr Manent. “That would mean that these cells can persist, contribute more to blood, and keep the mice healthy.”

The implications are significant. Targeting the function of these “fitness genes”, could one day boost the performance of HSCs derived from stem cells, making them transplant-ready. If such a treatment worked in humans, it might reduce the need for aggressive radiation prior to transplant, or even allow one donor’s marrow to help multiple patients.

Stem cells on demand?

That matters, because demand is high, and supply is low. Many people needing a bone marrow transplant can’t find a donor match. The holy grail of the field is to take a patient’s own cells, reprogram them into pluripotent stem cells, and derive fully functional, transplantable blood stem cells, no match required.

While that vision isn’t reality yet, research like Dr Manent’s is laying the groundwork. He hopes to publish results from the human cell experiments within the year, with patent filings in progress. In the meantime, Dr Manent’s work offers a vivid glimpse into how stem cells form, and how small molecular nudges might help shape their fate.

“It’s quite amazing,” says Dr Manent. “We’re watching the birth of the blood system, and learning how to rewrite it.”

About ARMI
The Australian Regenerative Medicine Institute (ARMI), based at Monash University in Melbourne, is a world leader in regenerative biology and stem cell research. ARMI works at the frontier of science, translating discovery into hope for people living with conditions like cancer, arthritis, and neurological injury.

Media Contact:
Emma Burrows, Communication Consultant ARMI.
M: 0417431376
E: emma.burrows@monash.edu